SCHEMBL136284

SCHEMBL136284

COC(=O)c1ccc(O)c(C(=O)O)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 5/20 0.67
CA2 P00918 5/20 0.67
CA12 O43570 4/20 0.67
CA7 P43166 4/20 0.67
CA9 Q16790 4/20 0.67
CA14 Q9ULX7 4/20 0.67
XDH P47989 2/20 0.67
KDM4E B2RXH2 4/20 0.59
ALDH1A1 P00352 3/20 0.59
HPGD P15428 3/20 0.59
HSD17B10 Q99714 3/20 0.59
LMNA P02545 3/20 0.59
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
MAPT P10636 2/20 0.59
HTT P42858 2/20 0.59
ALOX15 P16050 2/20 0.59
TP53 P04637 1/20 0.59
ALOX12 P18054 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL403210 0.89 CA12 (0.71) CA1CA2CA12CA7CA9
SCHEMBL9122345 0.85 CA12 (0.67) CA1CA2CA12CA7CA9
SCHEMBL29826125 0.85 CA1 (0.67) CA1CA2CA12CA7CA9
SCHEMBL1647438 0.85 CA12 (0.65) CA1CA2CA12CA7CA9
SCHEMBL670644 0.85 CA1 (0.67) CA1CA2CA12CA7CA9
SCHEMBL10400378 0.85 KDM4E (0.59) CA1CA2CA12CA7CA9
SCHEMBL552572 0.84 CA12 (0.65) CA1CA2CA12CA7CA9
SCHEMBL8768482 0.83 RAB9A (0.64) ALDH1A1HPGDMEN1KMT2AMAPT
SCHEMBL3767347 0.83 KDM4E (0.62) CA1CA2CA12CA7CA9
SCHEMBL9080431 0.83 KDM4E (0.62) CA1CA2CA12CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118240886-A Method for synthesizing ethyl salicylate compound by biological enzyme catalysis 济南大学 2024-06-25 CN claimed
US-9688807-B2 Epoxy resin system containing polyethylene tetraamines for resin transfer molding processes DOW GLOBAL TECHNOLOGIES LLC (US) 2017-06-27 US claimed
EP-2920227-B1 EPOXY RESIN SYSTEM CONTAINING POLYETHYLENE TETRAAMINES FOR RESIN TRANSFER MOLDING PROCESSES DOW GLOBAL TECHNOLOGIES LLC (US) 2017-02-08 EP claimed
EP-2920227-A1 EPOXY RESIN SYSTEM CONTAINING POLYETHYLENE TETRAAMINES FOR RESIN TRANSFER MOLDING PROCESSES Dow Global Technologies LLC (US) 2015-09-23 EP claimed
US-20150240025-A1 EPOXY RESIN SYSTEM CONTAINING POLYETHYLENE TETRAAMINES FOR RESIN TRANSFER MOLDING PROCESSES DOW EUROPE GMBH (CH) 2015-08-27 US claimed
WO-2014078219-A1 EPOXY RESIN SYSTEM CONTAINING POLYETHYLENE TETRAAMINES FOR RESIN TRANSFER MOLDING PROCESSES DOW GLOBAL TECHNOLOGIES LLC (US) 2014-05-22 WO claimed
CN-115160341-A Benzoxazine compound and pharmaceutical use thereof 中国医学科学院医学实验动物研究所 2022-10-11 CN disclosed
CN-112159347-B Preparation method of picolitamide 常州工程职业技术学院 2022-06-07 CN disclosed
CN-112159347-A Preparation method of picolitamide 常州工程职业技术学院 2021-01-01 CN disclosed
US-20200354319-A1 MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME UNIV CORNELL (US) 2020-11-12 US disclosed
US-9914740-B2 Tricyclic pyrido-carboxamide derivatives as rock inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2018-03-13 US disclosed
US-9914740-B2 Tricyclic pyrido-carboxamide derivatives as rock inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2018-03-13 US disclosed
US-9914740-B2 Tricyclic pyrido-carboxamide derivatives as rock inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2018-03-13 US disclosed
EP-1510210-A1 IMMUNITY-RELATED PROTEIN KINASE INHIBITORS Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-02 EP disclosed
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2004-12-23 US disclosed
EP-1489077-A1 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-22 EP disclosed
WO-2004052839-A1 ISOPHTALIC ACID DERIVATIVES BAYER HEALTHCARE AG (DE) 2004-06-24 WO disclosed
EP-1352650-A1 INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES Institute of Medicinal Molecular Design, Inc. (JP) 2003-10-15 EP disclosed
US-5872280-A RESPIRATORY SYSTEM DISORDERS BAYER AKTIENGESELLSCHAFT (DE) 1999-02-16 US disclosed
EP-0791576-A2 Leukotriene antagonistic benzoic acid derivatives BAYER AG (DE) 1997-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200354319-A1 MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME CALCOCO2, MDN1, MBNL1 CA1 1922/4885CA2 3617/4885CA12 3917/4885
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines NFKBIA, IL1B, IKBKB CA1 3456/4885CA2 1269/4885CA12 4370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.